IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024
15 Julio 2024 - 7:31AM
Business Wire
The Company to host an earnings conference call
via webcast
IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”)
(NASDAQ: IPA), an AI-driven biotherapeutic research and technology
company, will announce its full year fiscal 2024 financial results
and business highlights on Thursday, July 25, 2024, and will hold
an earnings call at 10:30 am Eastern Time the same day.
A live audio webcast of the earnings conference may be accessed
through a link that will be posted on IPA’s Investor Relations
website at ir.ipatherapeutics.com. A replay will be archived and
available for replay following the conference call.
Conference Call: Event Title: ImmunoPrecise Reports
Financial Results and Recent Business Highlights for Full Fiscal
Year 2024 Event Date: July 25th, 2024 Time: 10:30 AM (GMT-04:00)
Eastern Time (US and Canada)
***Participant Dial-In Details*** Participants call one
of the allocated dial-in numbers (below) and advise the Operator of
either the Conference ID 9236374 or Conference Name.
North America Toll-Free: (888) 550-5658 North America Toll:
(646) 960-0289 International Toll: +1(646) 960-0289
***Webcast Details *** Attendee URL:
https://events.q4inc.com/attendee/388047633
About ImmunoPrecise Antibodies Ltd.
The IPA Family is a biotherapeutic research and technology group
that leverages systems biology, multi-omics modelling and complex
artificial intelligence systems to support its proprietary
technologies in bioplatform-based antibody discovery. Services
include highly specialized, full-continuum therapeutic biologics
discovery, development, and out-licensing to support its business
partners in their quest to discover and develop novel biologics
against the most challenging targets. ImmunoPrecise Antibodies Ltd.
has several subsidiaries in North America and Europe including
entities such as Talem Therapeutics LLC, BioStrand BV,
ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies
(Europe) B.V. (collectively, the “IPA Family”). For further
information, visit www.ipatherapeutics.com.
Forward-Looking Statement:
This news release contains forward-looking statements within the
meaning of applicable United States securities laws and Canadian
securities laws. Forward-looking statements are often identified by
the use of words such as “potential”, “plans”, “expects” or “does
not expect”, “is expected”, “estimates”, “intends”, “anticipates”
or “does not anticipate”, or “believes”, or variations of such
words and phrases or state that certain actions, events or results
“may”, “could”, “would”, “might” or “will” be taken, occur or be
achieved. In respect of the forward-looking information contained
herein, IPA has provided such statements and information in
reliance on certain assumptions that management believed to be
reasonable at the time.
Forward-looking information involves known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements stated herein to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking information. Actual
results could differ materially from those currently anticipated
due to a number of factors and risks, as discussed in the Company’s
Annual Information Form dated July 10, 2023 (which may be viewed on
the Company’s profile at www.sedar.com), and the Company’s Form
40-F, dated July 10, 2023 (which may be viewed on the Company’s
profile at www.sec.gov). Should one or more of these risks or
uncertainties materialize, or should assumptions underlying the
forward-looking statements prove incorrect, actual results,
performance, or achievements may vary materially from those
expressed or implied by the forward-looking statements contained in
this news release. Accordingly, readers should not place undue
reliance on forward-looking information contained in this news
release. The forward-looking statements contained in this news
release are made as of the date of this release and, accordingly,
are subject to change after such date. The Company does not assume
any obligation to update or revise any forward-looking statements,
whether written or oral, that may be made from time to time by us
or on our behalf, except as required by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240715388760/en/
Investor contact: investors@ipatherapeutics.com
ImmunoPrecise Antibodies (NASDAQ:IPA)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
ImmunoPrecise Antibodies (NASDAQ:IPA)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024